- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

New landmark licensing agreement for Meningitis-B vaccine

In a new landmark licensing agreement towards addressing the challenge of Meningitis-B, the University of Oxford and Serum Institute of India Pvt. Ltd (SIIPL) have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation, delivering lifesaving protection against Meningitis-B through the production of a chimeric protein-based vaccine.

After five years of work, SIIPL and the Oxford team, led by Professor Christoph Tang, at the Sir William Dunn School of Pathology have formulated a quadrivalent vaccine consisting of four chimeric proteins to tackle Men-B. Preliminary results expected later this year indicate that the Oxford-SIIPL protein-based vaccine advances several aspects including improved safety, efficacy, and coverage compared to present-day licensed vaccines.

The ground-breaking MenFive® (Meningococcal ACYWX Polysaccharide Conjugate Vaccine), developed by SIIPL, builds upon the success of MenAfriVac® in eliminating Men-A disease from sub-Saharan Africa. Discussions are underway to implement MenFive® as a proactive strategy against meningococcal meningitis, further aligning with the WHO’s vision of defeating meningitis by 2030.

Simon Warner, Head of Licensing & Ventures – Life Sciences, Oxford University Innovation said: “The Meningitis-B vaccine agreement with the Serum Institute of India is another example of vaccine innovation at the University of Oxford. Oxford’s commitment and investment to develop efficacious, deployable vaccines will protect millions of lives and academic licensing and successful commercial partnerships that help solve global health challenges.”

Adar Poonawalla, CEO of Serum Institute of India Pvt. Ltd (SIIPL) said: “This partnership represents a monumental leap forward in our fight against meningitis, ensuring life-saving protection reaches those who need it most.

“This collaboration exemplifies a shared dedication to global health and underscores the importance of accessible vaccines. With long-standing partnerships and ongoing initiatives, our institutions remain steadfast in our shared goals to make a positive impact and reach communities in need worldwide. Together, we are shaping a healthier, safer future for all.”

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription